GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (NAS:HEPA) » Definitions » E10

Hepion Pharmaceuticals (Hepion Pharmaceuticals) E10 : $-2,869.01 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Hepion Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Hepion Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.560. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-2,869.01 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-06-02), Hepion Pharmaceuticals's current stock price is $1.28. Hepion Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was $-2,869.01. Hepion Pharmaceuticals's Shiller PE Ratio of today is .


Hepion Pharmaceuticals E10 Historical Data

The historical data trend for Hepion Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hepion Pharmaceuticals E10 Chart

Hepion Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -3,733.60

Hepion Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -3,740.90 -3,759.52 -3,733.60 -2,869.01

Competitive Comparison of Hepion Pharmaceuticals's E10

For the Biotechnology subindustry, Hepion Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hepion Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hepion Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Hepion Pharmaceuticals's Shiller PE Ratio falls into.



Hepion Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hepion Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.56/131.7762*131.7762
=-0.560

Current CPI (Mar. 2024) = 131.7762.

Hepion Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 2,656.840 100.560 3,481.603
201409 -783.984 100.428 -1,028.704
201412 -4,031.920 99.070 -5,363.003
201503 -3,695.930 99.621 -4,888.880
201506 -2,127.960 100.684 -2,785.098
201509 -2,463.950 100.392 -3,234.238
201512 -1,231.980 99.792 -1,626.834
201603 -1,567.970 100.470 -2,056.537
201606 -1,903.960 101.688 -2,467.315
201609 -1,455.970 101.861 -1,883.569
201612 -895.982 101.863 -1,159.100
201703 -1,343.970 102.862 -1,721.753
201706 209.996 103.349 267.757
201709 -895.982 104.136 -1,133.802
201712 -223.996 104.011 -283.790
201803 -377.992 105.290 -473.080
201806 -529.000 106.317 -655.678
201809 -885.400 106.507 -1,095.468
201812 -65.400 105.998 -81.305
201903 -160.600 107.251 -197.325
201906 -149.600 108.070 -182.417
201909 -10.600 108.329 -12.894
201912 -11.761 108.420 -14.295
202003 -19.400 108.902 -23.475
202006 -11.600 108.767 -14.054
202009 -13.800 109.815 -16.560
202012 -3.095 109.897 -3.711
202103 -2.400 111.754 -2.830
202106 -2.000 114.631 -2.299
202109 -2.400 115.734 -2.733
202112 -2.600 117.630 -2.913
202203 -1.820 121.301 -1.977
202206 -5.220 125.017 -5.502
202209 -2.240 125.227 -2.357
202212 -2.620 125.222 -2.757
202303 -3.480 127.348 -3.601
202306 -3.680 128.729 -3.767
202309 -2.740 129.860 -2.780
202312 -2.420 129.419 -2.464
202403 -0.560 131.776 -0.560

Add all the adjusted EPS together and divide 10 will get our e10.


Hepion Pharmaceuticals  (NAS:HEPA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Hepion Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Hepion Pharmaceuticals (Hepion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
399 Thornall Street, First Floor, Edison, NJ, USA, 08837
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
Executives
Peter Wijngaard director 8 SYLVAN WAY, PARSIPPANY NJ 07054
Robert T Foster officer: Chief Scientific Officer C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Kaouthar Lbiati director 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Anand Reddi director 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
John T Cavan officer: Chief Financial Officer C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob director, officer: CEO and President
Donald E Garlikov 10 percent owner 41 S. HIGH STREET, SUITE 3400, COLUMBUS OH 43215
Tamar D Howson director
Thomas Phd Adams director
Gabriel Cerrone 10 percent owner VIA SANT' ANDREA 18, MILAN L6 20121
John Z Sullivan-bolyai officer: Chief Medical Officer C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, 1ST FLOOR, EDISON NJ 08837
James Sapirstein director, officer: Chief Executive Officer 1517 SAN JACINTO, HOUSTON TX 77002
Arnold Lippa director C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
William Karl Hornung officer: Chief Financial Officer C/O CONTRAVIR PHARMACEUTICALS, INC., 420 LEXINGTON AVE., SUITE 300, NEW YORK NY 10170

Hepion Pharmaceuticals (Hepion Pharmaceuticals) Headlines

From GuruFocus